Literature DB >> 1916054

Simple empirical assessment of beta-cell function by a constant infusion of glucose test in normal and type 2 (non-insulin-dependent) diabetic subjects.

J C Levy1, A Rudenski, M Burnett, R Knight, D R Matthews, R C Turner.   

Abstract

The plasma insulin or C-peptide response to a 90-min constant glucose infusion 5 mg.kg ideal body weight-1.min-1 provides Beta-cell assessment comparable to more intensive methods. In 14 diet-treated Type 2 (non-insulin-dependent) diabetic subjects and 12 non-diabetic subjects, plasma insulin and C-peptide concentrations gave near linear plots against simultaneous glucose values. The 'glucose-insulin and glucose-C-peptide vectors' (G-I and G-C vectors), could be extrapolated to predict insulin and C-peptide levels during a 12 mmol/l hyperglycaemic clamp. Predicted concentrations correlated with clamp concentrations, r = 0.94 and r = 0.98 respectively, p less than 0.001, validating the vectors as empirical glucose dose-response curves. The vector slopes correlated highly with %Beta, a mathematical model-derived measure of Beta-cell function using constant infusion of glucose model assessment, Spearman r = 0.95 and 0.93 for insulin and C-peptide, respectively. G-I vector slopes in 21 diet-treated Type 2 diabetic subjects with fasting glucose (mean + 1 SD) 7.5 +/- 2.3 mmol/l, were lower than in 28 non-diabetic subjects, (geometric mean, 1 SD range, 8.4 pmol/mmol (3.3-21.0) and 25.1 pmol/mmol (14.3-44.1), p less than 0.001, respectively), indicating an impaired Beta-cell response. The G-I vector slopes correlated with obesity in both groups (r = 0.54 p less than 0.02 and 0.72, p less than 0.001 respectively), and, in 15 non-diabetic subjects, correlated inversely with insulin sensitivity as measured by a euglycaemic clamp (r = -0.66, p less than 0.01). Thus, Beta-cell function needs to be interpreted in relation to obesity/insulin resistance and, taking obesity into account, only 4 of 21 diabetic patients had Beta-cell function (G-I vector slope) in the non-diabetic range. The fasting plasma glucose in the diabetic subjects correlated inversely with the obesity-corrected G-I and G-C vector slopes (partial r = -0.57, p less than 0.01 and -0.86, p less than 0.001, respectively). The insulin or C-peptide response to the glucose infusion provides a direct empirical measure of the Beta-cell function, which can be interpreted in relation to obesity or to insulin resistance to assess underlying pancreatic responsiveness.

Entities:  

Mesh:

Substances:

Year:  1991        PMID: 1916054     DOI: 10.1007/bf00403285

Source DB:  PubMed          Journal:  Diabetologia        ISSN: 0012-186X            Impact factor:   10.122


  31 in total

1.  Decreased sensitivity of the pancreatic beta cells to glucose in prediabetic and diabetic subjects. A glucose dose-response study.

Authors:  E Cerasi; R Luft; S Efendic
Journal:  Diabetes       Date:  1972-04       Impact factor: 9.461

2.  Potentiation of insulin secretory responses by plasma glucose levels in man: evidence that hyperglycemia in diabetes compensates for imparied glucose potentiation.

Authors:  J B Halter; R J Graf; D Porte
Journal:  J Clin Endocrinol Metab       Date:  1979-06       Impact factor: 5.958

3.  Early response of plasma insulin to small doses of intravenous glucose: effect of obesity.

Authors:  R Pelkonen; M R Taskinen; E A Nikkilä
Journal:  J Clin Endocrinol Metab       Date:  1974-09       Impact factor: 5.958

4.  Insulin and glucose responses to identical oral glucose tolerance tests performed forty-eight hours apart.

Authors:  J M Olefsky; G M Reaven
Journal:  Diabetes       Date:  1974-05       Impact factor: 9.461

5.  Effect of transient elevation of plasma insulin within physiologic levels (simulated early insulin response) on blood glucose.

Authors:  J I Thorell
Journal:  J Clin Endocrinol Metab       Date:  1973-09       Impact factor: 5.958

6.  Hepatic glucose output in humans measured with labeled glucose to reduce negative errors.

Authors:  J C Levy; G Brown; D R Matthews; R C Turner
Journal:  Am J Physiol       Date:  1989-10

7.  Abnormal glucose modulation of islet A- and B-cell responses to arginine in non-insulin-dependent diabetes mellitus.

Authors:  G D Dimitriadis; G B Pehling; J E Gerich
Journal:  Diabetes       Date:  1985-06       Impact factor: 9.461

8.  Similar reduction of first- and second-phase B-cell responses at three different glucose levels in type II diabetes and the effect of gliclazide therapy.

Authors:  J P Hosker; A S Rudenski; M A Burnett; D R Matthews; R C Turner
Journal:  Metabolism       Date:  1989-08       Impact factor: 8.694

9.  Maintenance of basal plasma glucose and insulin concentrations in maturity-onset diabetes.

Authors:  R R Holman; R C Turner
Journal:  Diabetes       Date:  1979-03       Impact factor: 9.461

10.  Unbiased and flexible iterative computer program to achieve glucose clamping.

Authors:  D R Matthews; J P Hosker
Journal:  Diabetes Care       Date:  1989-02       Impact factor: 19.112

View more
  6 in total

1.  A genomewide search for type 2 diabetes-susceptibility genes in indigenous Australians.

Authors:  Frances Busfield; David L Duffy; Janine B Kesting; Shelley M Walker; Paul K Lovelock; David Good; Heather Tate; Denise Watego; Maureen Marczak; Noel Hayman; Joanne T E Shaw
Journal:  Am J Hum Genet       Date:  2001-12-12       Impact factor: 11.025

2.  Immunoradiometric assay of insulin, intact proinsulin and 32-33 split proinsulin and radioimmunoassay of insulin in diet-treated type 2 (non-insulin-dependent) diabetic subjects.

Authors:  P M Clark; J C Levy; L Cox; M Burnett; R C Turner; C N Hales
Journal:  Diabetologia       Date:  1992-05       Impact factor: 10.122

3.  Association of low birth weight with beta cell function in the adult first degree relatives of non-insulin dependent diabetic subjects.

Authors:  J T Cook; J C Levy; R C Page; J A Shaw; A T Hattersley; R C Turner
Journal:  BMJ       Date:  1993-01-30

4.  Changes in insulin resistance indicators, IGFs, and adipokines in a year-long trial of aerobic exercise in postmenopausal women.

Authors:  Christine M Friedenreich; Heather K Neilson; Christy G Woolcott; Anne McTiernan; Qinggang Wang; Rachel Ballard-Barbash; Charlotte A Jones; Frank Z Stanczyk; Rollin F Brant; Yutaka Yasui; Melinda L Irwin; Kristin L Campbell; Margaret L McNeely; Kristina H Karvinen; Kerry S Courneya
Journal:  Endocr Relat Cancer       Date:  2011-06-08       Impact factor: 5.678

5.  Lixisenatide as add-on treatment among patients with different β-cell function levels as assessed by HOMA-β index.

Authors:  Riccardo C Bonadonna; Lawrence Blonde; Mikhail Antsiferov; Rachele Berria; Pierre Gourdy; Mensud Hatunic; Viswanathan Mohan; Michael Horowitz
Journal:  Diabetes Metab Res Rev       Date:  2017-06-20       Impact factor: 4.876

6.  National trends in insulin resistance and β-cell dysfunction among adults with prediabetes: NHANES 2001-2016.

Authors:  Hao-Jie Zhang; Xiao Tan; Ning-Jian Wang
Journal:  Chronic Dis Transl Med       Date:  2021-01-07
  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.